Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE2

מצבים רפואיים

Chronic Graft-versus-host Disease (cGVHD)

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

Univ of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Contact: Principal Investigator (Noa Holtzman, MD)
Moffitt Cancer Center, Tampa, Florida, United States
Contact: Principal Investigator (Farhad Khimani, MD)
Melissa Alsina, MD (Sub-investigator)
Nelli Bejanyan, MD (Sub-investigator)
Omar Castaneda Puglianini, MD (Sub-investigator)
Hany Elmariah, MD (Sub-investigator)
Rawan Faramand, MD (Sub-investigator)
Ciara Freeman, MD, PhD (Sub-investigator)
Doris Hansen, MD (Sub-investigator)
Michael Jain, MD, PhD (Sub-investigator)
Aleksandr Lazaryan, MD, PhD (Sub-investigator)
Hien Liu, MD (Sub-investigator)
Frederick Locke, MD (Sub-investigator)
Sayeef Mirza, MD (Sub-investigator)
Asmita Mishra, MD (Sub-investigator)
Taiga Nishihori, MD (Sub-investigator)
Jose Ochoa-Bayona, MD (Sub-investigator)
Lia Perez, MD (Sub-investigator)
Fabiana Perna, MD, PhD (Sub-investigator)
Joseph Pidala, MD, PhD (Sub-investigator)
University of Kansas Cancer Center, Kansas City, Kansas, United States
Contact: Principal Investigator (Muhammad Umair Mushtaq, MD)
University of Virginia Comprehensive Cancer Center, Charlottesville, Virginia, United States
Contact: Principal Investigator (Indumathy Varadarajan, MD)
Virginia Commonwealth University, Richmond, Virginia, United States
Contact: Principal Investigator (William Clark, MD)

מובילי המחקר